Business Context and Reporting Period
This Form 8-K is a current report filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on August 14, 2024. The filing serves to announce the company's financial results for the three and six months ended June 30, 2024. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol RSLS.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data. It references a press release (Exhibit 99.1) for detailed figures. Consequently, the following metrics are not provided in this document:
- Revenue
- Net Profit or Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Material Changes
The filing text does not disclose specific material changes in financial performance compared to prior periods. It only confirms that results for the periods ended June 30, 2024, have been issued.
Guidance, Outlook, and Risks
The document does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Verify Company Identity: Confirm the filing is for ReShape Lifesciences Inc. (RSLS), as the request metadata incorrectly listed Vyome Holdings, Inc.
- Review Exhibit 99.1: Access the attached press release to obtain actual revenue, profit, and cash flow numbers for the three and six months ended June 30, 2024.
- Check Legal Status: Note that the financial data in this 8-K is "furnished" and not "filed," which may impact liability protections for the information provided.
- Confirm Reporting Period: Ensure analysis is based on the Q2 2024 and YTD 2024 periods ending June 30, 2024.